El Paso, TXNCT07681271Now EnrollingIRB Ready

Papulopustular Rosacea Clinical Trial in El Paso, TX

Access cutting-edge papulopustular rosacea treatment through this clinical trial at a research site in El Paso. Study-provided care at no cost to qualified participants.

Sponsored by Novartis Pharmaceuticals

Quick Self-Assessment

See if you qualify for this El Paso location

Preparing your pre-screening questions…

Expert Care in El Paso

Access papulopustular rosacea specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related papulopustular rosacea treatment provided free

Apply for This El Paso Location

Check if you qualify for this papulopustular rosacea clinical trial in El Paso, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to El Paso

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit El Paso site if eligible
  4. 4Begin participation

About This Papulopustular Rosacea Study in El Paso

This Phase 2 study aims to evaluate whether Bruton's tyrosine kinase (BTK) inhibition with remibrutinib can produce a clinically meaningful reduction in inflammatory lesions in adults with moderate-to-severe papulopustular rosacea, while also assessing safety and tolerability of remibrutinib in this indication.

Sponsor: Novartis Pharmaceuticals

Who Can Participate

Inclusion Criteria

Signed informed consent must be obtained prior to participation in the study.
Adult ≥18 years with a clinical diagnosis of PPR.
Moderate-to-severe disease defined by a modified Investigator's Global Assessment (IGA) score of 3 or 4
The presence of 15 - 60 inflammatory (papular/pustular, max. 2 nodular) facial lesions at screening, with at least 15 lesions present at Day 1 (Baseline).
Completed requisite washout of systemic antibiotics (30 days) and other prohibited systemic therapies before randomization.
Willingness to refrain from initiating treatments or undergoing procedures that target or impact PPR during the double-blind period, and to use only protocol-allowed products. Key

Exclusion Criteria

Presence of more than 2 nodular inflammatory lesions
Any active facial dermatoses or skin disease or condition that may interfere with assessment of PPR (e.g., seborrheic dermatitis, perioral dermatitis, acne, acneiform eruptions from biologic medications, steroid-induced dermatitis resembling rosacea or acne).
History of hypersensitivity to any of the study treatments or its excipients or to drugs of similar chemical classes
Use of biologics within five half-lives prior to screening or until the expected pharmacodynamic (PD) effect has returned to baseline, whichever is longer; or longer if required by local regulations
Use of small molecules and/or immunosuppressants that are not corticosteroids within 5 half-lives or within 30 days prior to screening, whichever is longer; or longer if required by local regulations
Any use of systemic corticosteroids, systemic antibiotics, or topical treatments (including corticosteroids, antibiotics, ivermectin, azelaic acid, or metronidazole) within 30 days prior to randomization, or any planned use of these agents during the study treatment period.
History of live attenuated vaccine within 6 weeks prior to randomization or requirement to receive these vaccinations at any time while on study treatment.
Use, planned use, or failure to meet the protocol-defined washout periods for prohibited therapies. In particular, patients with pretreatment with remibrutinib or another BTK-inhibitor within 4 months prior to randomization. Other protocol-defined inclusion/exclusion criteria may apply.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in El Paso?

Yes, this clinical trial (NCT07681271) has an active research site in El Paso, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Papulopustular Rosacea Treatment Options in El Paso, TX

If you're searching for papulopustular rosacea treatment options in El Paso, TX, this clinical trial (NCT07681271) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our El Paso research site is actively enrolling participants for this clinical trial. You'll receive care from experienced papulopustular rosacea specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all papulopustular rosacea clinical trials near you to find additional studies recruiting in your area.

More Sleep Apnea Trials in El Paso, TX

See all sleep apnea clinical trials recruiting in El Paso — not just this study.

Browse Sleep Apnea Trials in El Paso →

Browse More Trials by Condition

Sleep Apnea TrialsRosacea TrialsAll Conditions →

Ready to Join in El Paso?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · El Paso, TX